Trials / No Longer Available
No Longer AvailableNCT03559660
CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
Compassionate Use Program Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The objective of this program is to allow treating physicians to supply/continue to supply Certolizumab Pegol (CIMZIA®, CZP) to adults suffering from Crohn's Disease (CD), and who are considered not suitable for treatment, intolerant, have medical contraindications or had insufficient response with an authorized conventional therapy, including other authorized biologics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certolizumab Pegol |
Timeline
- First posted
- 2018-06-18
- Last updated
- 2025-06-11
Source: ClinicalTrials.gov record NCT03559660. Inclusion in this directory is not an endorsement.